» Articles » PMID: 34291273

Fluorescent Kinase Inhibitors As Probes in Cancer

Overview
Journal Chem Soc Rev
Specialty Chemistry
Date 2021 Jul 22
PMID 34291273
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Fluorescent dyes attached to kinase inhibitors (KIs) can be used to probe kinases in vitro, in cells, and in vivo. Ideal characteristics of the dyes vary with their intended applications. Fluorophores used in vitro may inform on kinase active site environments, hence the dyes used should be small and have minimal impact on modes of binding. These probes may have short wavelength emissions since blue fluorophores are perfectly adequate in this context. Thus, for instance, KI fragments that mimic nucleobases may be modified to be fluorescent with minimal perturbation to the kinase inhibitor structure. However, progressively larger dyes, that emit at longer wavelengths, are required for cellular and in vivo work. In cells, it is necessary to have emissions above autofluorescence of biomolecules, and near infrared dyes are needed to enable excitation and observation through tissue in vivo. This review is organized to describe probes intended for applications in vitro, in cells, then in vivo. The readers will observe that the probes featured tend to become larger and responsive to the near infared end of the spectrum as the review progresses. Readers may also be surprised to realize that relatively few dyes have been used for fluorophore-kinase inhibitor conjugates, and the area is open for innovations in the types of fluorophores used.

Citing Articles

Design Principles and Applications of Fluorescent Kinase Inhibitors for Simultaneous Cancer Bioimaging and Therapy.

Ganai A, Vrettos E, Kyrkou S, Zoi V, Khan Pathan T, Karpoormath R Cancers (Basel). 2024; 16(21).

PMID: 39518106 PMC: 11545566. DOI: 10.3390/cancers16213667.


Cytotoxicities of Tumor-Seeking Dyes: Impact on Future Clinical Trials.

Usama S, Gao Z, Arancillo M, Burgess K ChemMedChem. 2023; 18(5):e202200561.

PMID: 36630600 PMC: 10010615. DOI: 10.1002/cmdc.202200561.


Intrinsically Fluorescent Anti-Cancer Drugs.

Kabir M, Wang F, Clayton A Biology (Basel). 2022; 11(8).

PMID: 36009762 PMC: 9405238. DOI: 10.3390/biology11081135.


Conjugation of Palbociclib with MHI-148 Has an Increased Cytotoxic Effect for Breast Cancer Cells and an Altered Mechanism of Action.

Choi P, Tomek P, Tercel M, Reynisson J, Park T, Cooper E Molecules. 2022; 27(3).

PMID: 35164144 PMC: 8840619. DOI: 10.3390/molecules27030880.

References
1.
Jorge S, Schulman S, Freed J, VanderLaan P, Rangachari D, Kobayashi S . Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. Lung Cancer. 2016; 90(3):369-74. PMC: 4724060. DOI: 10.1016/j.lungcan.2015.10.028. View

2.
Liu Z, Pourghiasian M, Radtke M, Lau J, Pan J, Dias G . An organotrifluoroborate for broadly applicable one-step 18F-labeling. Angew Chem Int Ed Engl. 2014; 53(44):11876-80. DOI: 10.1002/anie.201406258. View

3.
Ethirajan M, Chen Y, Joshi P, Pandey R . The role of porphyrin chemistry in tumor imaging and photodynamic therapy. Chem Soc Rev. 2010; 40(1):340-62. DOI: 10.1039/b915149b. View

4.
Levitt D, Levitt M . Human serum albumin homeostasis: a new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements. Int J Gen Med. 2016; 9:229-55. PMC: 4956071. DOI: 10.2147/IJGM.S102819. View

5.
Jiang Z, Pflug K, Usama S, Kuai D, Yan X, Sitcheran R . Cyanine-Gemcitabine Conjugates as Targeted Theranostic Agents for Glioblastoma Tumor Cells. J Med Chem. 2019; 62(20):9236-9245. PMC: 7050787. DOI: 10.1021/acs.jmedchem.9b01147. View